OXFORD UNIV PRESS

• 

  Publisher Of

  • Effect of cytochrome P450 on the response of olfactory receptor.  Chemical Senses.  41:E159-E159. 2016
  • Examining the variable influence of population structure on odor perception.  Chemical Senses.  41:E255-E255. 2016
  • Improving the odorant sensitivity of olfactory receptor-expressing yeast with accessory proteins.  Chemical Senses.  41:E211-E211. 2016
  • Mammalian odorant receptors: Heterologous expression and deorphanization.  Chemical Senses.  41:E123-E123. 2016
  • Molecular dynamics simulations reveal the ligand-dependent activation of hOR7D4.  Chemical Senses.  41:E157-E157. 2016
  • Olfactory receptor accessory proteins RTP1 and RTP2 play a crucial role in receptor gene choice, development and odor detection.  Chemical Senses.  41:E253-E253. 2016
  • Receptor repertoire for aversive odorants.  Chemical Senses.  41:E252-E252. 2016
  • Synergistic control of olfactory receptor trafficking to the cell surface membrane in heterologous cells.  Chemical Senses.  41:E252-E252. 2016
  • Vapor detection and discrimination with a panel of odorant receptors expressed in heterologous cells.  Chemical Senses.  41:E262-E263. 2016
  • Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.  European Heart Journal.  35:138-138. 2014
  • Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.  European Heart Journal.  34:787-787. 2013
  • Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.  European Heart Journal.  32:964-964. 2011
  • Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.  European Heart Journal.  32:166-166. 2011
  • The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.  European Heart Journal.  32:134-134. 2011
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.  European Heart Journal.  32:872-872. 2011
  • Early in-ospital worsening heart failure predicts adverse outcome in patients.  European Heart Journal.  30:719-719. 2009
  • Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.  European Heart Journal.  30:115-115. 2009
  • Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).  European Heart Journal.  30:424-425. 2009
  • Impact of anemia in patients with pulmonary hypertension.  European Heart Journal.  30:260-260. 2009
  • Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.  European Heart Journal.  30:6-6. 2009
  • Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.  European Heart Journal.  30:811-811. 2009
  • Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.  European Heart Journal.  30:164-164. 2009
  • Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.  European Heart Journal.  30:276-276. 2009
  • Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.  European Heart Journal.  30:445-446. 2009
  • Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.  European Heart Journal.  30:876-876. 2009
  • Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.  European Heart Journal.  30:899-900. 2009
  • Racial disparities in survival in patients with pulmonary hypertension.  European Heart Journal.  30:513-513. 2009
  • Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.  European Heart Journal.  30:424-424. 2009
  • Worsening renal function in acute heart failure: change in BP and effects of relaxin.  European Heart Journal.  30:1020-1021. 2009
  • SPECT myocardial perfusion imaging is a strong predictor of sudden cardiac death in patients with coronary artery disease.  European Heart Journal, Supplement.  11:S52-S52. 2009
  • RAPID INHIBITION OF PROGRESSION OF STRUCTURAL DAMAGE WITH CERTOLIZUMAB PEGOL, A NOVEL SC PEGYLATED, FC-FREE ANTI-TNF.  Rheumatology (Oxford, England).  48:I18-I18. 2009
  • 3-HYDROXYKYNURENINE AND COGNITIVE IMPAIRMENT IN FIRST-EPISODE NEUROLEPTIC-NAIVE PATIENTS WITH SCHIZOPHRENIA.  Schizophrenia Bulletin.  35:151-151. 2009
  • Artificial Sweeteners and Metallic Taste: Role of TRP Channel.  Chemical Senses.  34:E27-E27. 2009
  • EFFICACY AND TOLERABILITY OF ADJUNCTIVE ARMODAFINIL IN PATIENTS WITH SCHIZOPHRENIA.  Schizophrenia Bulletin.  35:356-357. 2009
  • NEUROSTEROIDS AS NOVEL THERAPEUTIC AGENTS IN SCHIZOPHRENIA AND PTSD.  Schizophrenia Bulletin.  35:368-368. 2009
  • Odorant Receptor Polymorphisms and Olfactory Perception.  Chemical Senses.  34:E27-E27. 2009
  • Synchronization of the Taste - Reward System Improves Discrimination in a Taste Guided Task.  Chemical Senses.  34:E15-E15. 2009
  • A Putative Endoplasmic Reticulum Chaperone, Calreticulin 4, is Expressed in Mouse Vomeronasal Organ.  Chemical Senses.  33:S92-S92. 2008
  • Functional Expression of Mammalian Odorant Receptors by RTP Family Members.  Chemical Senses.  33:S19-S19. 2008
  • Nicotinic Acetylcholine Receptors (NACHRS): Novel Bitter Taste Receptors for Nicotine.  Chemical Senses.  33:S113-S113. 2008
  • Odor Coding by a Mammalian Receptor Repertoire.  Chemical Senses.  33:S1-S1. 2008
  • Positive Selection Shapes the Function of an Odorant Receptor for Sex-Steroid Derived Odors in Primates.  Chemical Senses.  33:S50-S50. 2008
  • Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.  European Heart Journal.  29:513-513. 2008
  • An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.  European Heart Journal.  29:328-328. 2008
  • Cognitive function and anticoagulation control in patients with atrial fibrillation.  European Heart Journal.  29:258-258. 2008
  • Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.  European Heart Journal.  29:284-285. 2008
  • Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.  European Heart Journal.  29:326-326. 2008
  • Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.  European Heart Journal.  29:124-124. 2008
  • Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).  European Heart Journal.  29:679-679. 2008
  • Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.  European Heart Journal.  29:137-138. 2008
  • Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.  European Heart Journal.  29:447-447. 2008
  • Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.  European Heart Journal.  29:5-5. 2008
  • Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.  European Heart Journal.  29:7-7. 2008
  • Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.  European Heart Journal.  29:345-346. 2008
  • A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.  European Heart Journal.  28:59-59. 2007
  • Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.  European Heart Journal.  28:59-59. 2007
  • Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.  European Heart Journal.  28:259-260. 2007
  • Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.  European Heart Journal.  28:516-516. 2007
  • Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.  European Heart Journal.  28:689-689. 2007
  • Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.  European Heart Journal.  28:184-184. 2007
  • Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.  European Heart Journal.  28:577-577. 2007
  • Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.  European Heart Journal.  28:660-660. 2007
  • Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.  European Heart Journal.  28:9-9. 2007
  • Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.  European Heart Journal.  28:218-218. 2007
  • The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.  European Heart Journal.  28:187-187. 2007
  • Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.  European Heart Journal.  28:384-385. 2007
  • Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.  European Heart Journal.  26:431-431. 2005
  • Untitled.  Military Medicine.  170:II-+. 2005
  • Diabetes mellitus after atypical antipsychotic agents: a retrospective cohort study of a large outpatient population.  European Journal of Public Health.  14:75-75. 2004
  • Fractures in the elderly: Predictors, occurrence and consequences: the Canadian Study of Health and Aging (CSHA).  European Journal of Public Health.  14:86-86. 2004
  • Zero tolerance: Policing a free society.  British Journal of Social Work.  28:285-288. 1998
  • Basic principles of information technology organization in health care institutions - Questions and answers.  Journal of the American Medical Informatics Association : Jamia.  4:S36-S40. 1997
  • The radiation of vascular plants 2004
  • A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).  Annals of Oncology. 353-353. 2019
  • A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer.  Annals of Oncology. 2019
  • ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups.  Annals of Oncology. 332-+. 2019
  • Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE.  European Heart Journal. 2956-2956. 2019
  • Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy.  European Heart Journal. 2243-2243. 2019
  • BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study.  Annals of Oncology. 2019
  • Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study.  European Heart Journal. 3353-3353. 2019
  • Cell-Free DNA to detect focal versus non-focal MET amplification in metastatic colorectal cancer patients: Combined analysis from Japan and the United States.  Annals of Oncology. 32-32. 2019
  • Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial.  European Heart Journal. 531-531. 2019
  • Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD.  Annals of Oncology. 2019
  • Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy.  European Heart Journal. 2474-2474. 2019
  • Expression of x-linked inhibitor of apoptosis protein (XIAP) and its association with clinicopathological parameters in invasive breast cancers.  Annals of Oncology. 92-+. 2019
  • Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial.  European Heart Journal. 182-182. 2019
  • Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation.  European Heart Journal. 2951-2951. 2019
  • Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC).  Annals of Oncology. 2019
  • Implementing a cancer survivorship program for individuals with recurrent breast cancer.  Annals of Oncology. 830-830. 2019
  • Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial.  European Heart Journal. 51-51. 2019
  • Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study.  European Heart Journal. 65-65. 2019
  • Network characteristics of a hypertension referral system in western kenya.  European Heart Journal. 3973-3973. 2019
  • Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study.  European Heart Journal. 2978-2978. 2019
  • Outcomes of catheter ablation for atrial fibrillation based on sex: data from the cabana trial.  European Heart Journal. 1776-1776. 2019
  • Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1.  European Heart Journal. 2629-2629. 2019
  • Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours.  Annals of Oncology. 2019
  • Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours.  Annals of Oncology. 163-+. 2019
  • Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study.  European Heart Journal. 1222-1222. 2019
  • Predictors of atrial fibrillation in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial.  European Heart Journal. 92-92. 2019
  • Risk of stroke in hypertensive patients with atrial fibrillation treated with oral anticoagulants.  European Heart Journal. 3709-3709. 2019
  • Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial.  Annals of Oncology. 2019
  • Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis.  European Heart Journal. 1514-1514. 2019
  • Expression of the G protein coupled odorant receptors.  Chemical Senses. E49-E49. 2019
  • Interacting Ig Superfamily Proteins Organize Axon Terminals of Olfactory Receptor Neurons Regulated by Olfactory Receptors in Drosophila.  Chemical Senses. E68-E68. 2019
  • Mapping Olfaction Through Transcriptome Profiling.  Chemical Senses. E25-E25. 2019
  • Olfactory experience with semiochemicals influences sex-specific olfactory receptor expression.  Chemical Senses. E95-E96. 2019
  • Targeted transcriptomics of olfactory receptors for high-throughput mapping of olfactory bulb glomeruli.  Chemical Senses. E111-E112. 2019
  • A NOVEL HETEROZYGOUS MISSENSE MUTATION OF WILMS' TUMOR 1 MAY CAUSE FSGS THROUGH DYSREGULATED EXPRESSION OF ARHGAP24.  Nephrology Dialysis Transplantation. 2019
  • THE LMX1 beta R246Q MUTATION INDUCES PODOCYTE INJURY THROUGH DYSREGULATION OF CHOLESTEROL TRANSPORT GENE EXPRESSION.  Nephrology Dialysis Transplantation. 2019
  • Location of odorant-receptor interaction within OR1A1 binding cavity is crucial for their activation potential.  Chemical Senses. E16-E16. 2019
  • Pharmacology of odorant interactions at odorant receptors in vivo.  Chemical Senses. E9-E9. 2019
  • Chemical Adducts of Flavorants in E-cigarette Liquid Solvents Act As Modulators of Respiratory Irritant Receptors.  Chemical Senses. E238-E238. 2018
  • Consensus Odorant Receptors Support Robust Cell Surface Expression in Non-Olfactory Cells.  Chemical Senses. E186-E186. 2018
  • Experience dependent axon targeting in the olfactory system.  Chemical Senses. E249-E249. 2018
  • Interactions of Odorants at Odorant Receptors In Vivo Correlate with Perceptions of Odor Mixtures.  Chemical Senses. E167-E168. 2018
  • Vapor detection and discrimination with a panel of odorant receptors expressed in heterologous cells.  Chemical Senses. E185-E185. 2018
  • Agent Orange exposure in veterans with heart failure.  European Heart Journal. 377-377. 2018
  • Association of hepatic steatosis with adverse cardiovascular events: insights from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial.  European Heart Journal. 1286-1286. 2018
  • Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial.  European Heart Journal. 318-318. 2018
  • Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry.  European Heart Journal. 1250-1250. 2018
  • Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial.  European Heart Journal. 31-32. 2018
  • Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis.  European Heart Journal. 7-8. 2018
  • Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial.  European Heart Journal. 868-868. 2018
  • Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure?.  European Heart Journal. 166-166. 2018
  • Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial.  European Heart Journal. 897-897. 2018
  • Characterization of major and clinically relevant non-major bleeding in the APEX trial.  European Heart Journal. 1264-1265. 2018
  • Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine.  European Heart Journal. 871-871. 2018
  • Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL.  European Heart Journal. 1082-1082. 2018
  • Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial.  European Heart Journal. 196-196. 2018
  • Evaluation the predictive value of PARIS score for long-term out-of-hospital events after percutaneous coronary interventions.  European Heart Journal. 1354-1354. 2018
  • Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE.  European Heart Journal. 1231-1231. 2018
  • LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS.  European Heart Journal. 399-400. 2018
  • Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study.  European Heart Journal. 1083-1084. 2018
  • Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial.  European Heart Journal. 836-837. 2018
  • Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial.  European Heart Journal. 1007-1007. 2018
  • Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial.  European Heart Journal. 431-431. 2018
  • Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation.  European Heart Journal. 818-819. 2018
  • A genetic and genomics approach identifies novel pathways of human antifungal immune responses.  Medical Mycology. S61-S61. 2018
  • Multi-center study of Mucorales and other mould contamination of freshly-laundered linens arriving at US healthcare facilities.  Medical Mycology. S40-S40. 2018
  • Novel FK506 analog exhibits anti-fungal activity against Cryptococcus neoformans in vitro and in an animal model.  Medical Mycology. S139-S139. 2018
  • Obtainment and phenotypic characterization of amutant strain for the putative ATL gene in the Cryptococcus neoformans JF289 strain.  Medical Mycology. S129-S129. 2018
  • Sexual reproduction and the evolution of eukaryotic microbial pathogens.  Medical Mycology. S7-S7. 2018
  • Genetic and Demographic Influences on Odor Perception.  Chemical Senses. E107-E107. 2018
  • Social Communication of Condition-Dependent Olfactory Signals in Strepsirrhine Primates.  Chemical Senses. E7-E7. 2018
  • TRP Ion Channels as Key Targets of Tobacco and Electronic Cigarette Irritants and Flavor Additives.  Chemical Senses. E4-E4. 2018
  • The Receptor Logic Behind Varying Odorant Concentrations.  Chemical Senses. E105-E105. 2018
  • CLINICAL AND FUNCTIONAL OUTCOMES IN YOUNG ADULTHOOD OF CHILDREN WITH PSYCHOTIC SYMPTOMS: A LONGITUDINAL TWIN COHORT STUDY.  Schizophrenia Bulletin. S97-S97. 2018
  • EPIGENETIC SIGNATURES OF CHILDHOOD AND ADOLESCENT VICTIMISATION USING A GENETICALLY SENSITIVE LONGITUDINAL COHORT STUDY.  Schizophrenia Bulletin. S25-S25. 2018
  • LONGITUDINAL WORKING MEMORY FUNCTIONAL DYSCONNECTIVITY REFLECTS HETEROGENEITY IN INDIVIDUALS AT ULTRA HIGH RISK FOR PSYCHOSIS.  Schizophrenia Bulletin. S281-S281. 2018
  • PROTECTIVE FACTORS FOR PSYCHOTIC EXPERIENCES AMONGST ADOLESCENTS EXPOSED TO MULTIPLE FORMS OF VICTIMIZATION.  Schizophrenia Bulletin. S110-S110. 2018
  • Evolution of olfaction: What did the modern human lose?.  Chemical Senses. E21-E21. 2018
  • The Receptor Repertoires Behind Varying Odorant Concentrations.  Chemical Senses. E14-E14. 2018
  • Antigenic response to CT-P13 and remicade in inflammatory bowel disease patients shows similar epitope recognition.  Journal of Crohns & Colitis. S381-S382. 2018
  • A phase 2 study of CMB305 and atezolizumab in NY-ESO-1+soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival.  Annals of Oncology. 2017
  • AGITG NABNEC: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.  Annals of Oncology. 2017
  • Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer.  Annals of Oncology. 2017
  • KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC).  Annals of Oncology. 2017
  • Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).  Annals of Oncology. 2017
  • Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.  Annals of Oncology. 2017
  • Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).  Annals of Oncology. 2017
  • Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy).  Annals of Oncology. 2017
  • QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML).  Annals of Oncology. 2017
  • A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials.  European Heart Journal. 1221-1221. 2017
  • Association between the timing of surgery for complicated infective endocarditis and survival.  European Heart Journal. 956-956. 2017
  • Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin.  European Heart Journal. 776-776. 2017
  • Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF).  European Heart Journal. 781-782. 2017
  • Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease.  European Heart Journal. 1080-1080. 2017
  • Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy.  European Heart Journal. 382-382. 2017
  • INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin.  European Heart Journal. 576-576. 2017
  • Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial.  European Heart Journal. 760-761. 2017
  • Pre- and post-stroke antithrombotic therapy in atrial fibrillation patients - a Danish nation-wide registry-based study.  European Heart Journal. 884-884. 2017
  • Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials.  European Heart Journal. 997-997. 2017
  • Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial.  European Heart Journal. 780-780. 2017
  • The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial.  European Heart Journal. 608-608. 2017
  • The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID.  European Heart Journal. 1081-1082. 2017
  • Ticagrelor in patients with symptomatic peripheral artery disease and prior coronary artery disease.  European Heart Journal. 452-452. 2017
  • Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial.  European Heart Journal. 188-188. 2017
  • Impact of the sterol 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol on tumor-pathological features, prognosis and response to statin treatment in breast cancer.  Annals of Oncology. 2017
  • Comparison of chemoradiotherapy treatment strategies in stage III non-small cell lung cancer among elderly patients from multiple data sources.  Annals of Oncology. 2017
  • SAFETY FOLLOWING INITIATION OF RITUXIMAB IN GRANULOMATOSIS WITH POLYANGIITIS (GPA) OR MICROSCOPIC POLYANGIITIS (MPA): INTERIM ANALYSIS OF THE RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS REGISTRY (RAVER).  Rheumatology (Oxford, England). 158-158. 2017
  • Stability and plasticity in the Drosophila olfactory system across timescales.  Chemical Senses. E3-E3. 2017
  • A phase 1, first-in-human dose escalation study of ETC-159 in advanced or metastatic solid tumours.  Annals of Oncology. 2016
  • A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.  Annals of Oncology. 2016
  • Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC).  Annals of Oncology. 2016
  • Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP).  Annals of Oncology. 2016
  • Refinement of Olfactory Receptor Transcribed Regions Improves the Accuracy of In Vivo Receptor Deorphanization.  Chemical Senses. E83-E83. 2016
  • Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis.  European Heart Journal. 128-128. 2016
  • Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study.  European Heart Journal. 30-30. 2016
  • Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy.  European Heart Journal. 1249-1249. 2016
  • Multinational ethnic variations in self-reported health status in chronic heart failure patients.  European Heart Journal. 534-535. 2016
  • Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation.  European Heart Journal. 500-500. 2016
  • Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial.  European Heart Journal. 233-234. 2016
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF).  European Heart Journal. 686-686. 2016
  • Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF).  European Heart Journal. 685-685. 2016
  • Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF.  European Heart Journal. 330-330. 2016
  • Prognostic Utility of GDF-15 in Chronic Heart Failure: Insights From the HF-ACTION Study.  European Heart Journal. 441-441. 2016
  • Systemic embolization in patients with atrial fibrillation: results from ROCKET AF.  European Heart Journal. 511-511. 2016
  • The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class.  European Heart Journal. 405-405. 2016
  • Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ).  Annals of Oncology. 108-108. 2016
  • Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.  Annals of Oncology. 74-75. 2015
  • AGE, SEX, DRINKING, AND THE ADOLESCENT BRAIN CORTEX: INITIAL FINDINGS FROM NATIONAL CONSORTIUM ON ALCOHOL & NEURODEVELOPMENT IN ADOLESCENCE.  Alcohol and Alcoholism (Oxford, Oxfordshire). 2015
  • Experience-dependent Axon Targeting and Guidance Molecule Expression in the Mouse Olfactory System.  Chemical Senses. 629-629. 2015
  • Identification of key residues involved in activation of G-protein Coupled Odorant Receptors.  Chemical Senses. 654-654. 2015
  • Menthol Attenuates Chemosensory Irritation and Elevates blood Cotinine in Cigarette Smoke Exposed Mice.  Chemical Senses. 596-596. 2015
  • Metabolites as preferred ligands for the human olfactory receptors outside "the olfactory box".  Chemical Senses. 655-656. 2015
  • Molecular profiling of activated olfactory neurons using phosphorylated ribosome immunoprecipitation and RNA-Seq identifies odorant receptors responding to odors in vivo.  Chemical Senses. 562-562. 2015
  • Nicotine addiction: molecular basis of behaviors at the complex interface between reward, food intake and taste.  Chemical Senses. 535-535. 2015
  • Olfactory receptor accessory proteins RTP1 and RTP2 play a crucial role in receptor gene choice, development and odor detection.  Chemical Senses. 535-535. 2015
  • Permissive Binding Pocket and Low Activation Threshold Underlie Exceptionally Broad Responsiveness of Some G-Protein Coupled Odorant Receptors.  Chemical Senses. 633-633. 2015
  • Predicting human odor perception from olfactory receptor activation.  Chemical Senses. 551-551. 2015
  • Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy.  European Heart Journal. 1041-1042. 2015
  • Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial.  European Heart Journal. 1104-1104. 2015
  • Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial.  European Heart Journal. 1068-1068. 2015
  • Effect of ivabradine on heart rate variability in patients with stable coronary artery disease.  European Heart Journal. 1088-1088. 2015
  • Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial.  European Heart Journal. 339-339. 2015
  • External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation.  European Heart Journal. 710-711. 2015
  • Hypotension in patients with acute heart failure: Insights from RELAX-AHF.  European Heart Journal. 1051-1052. 2015
  • Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery.  European Heart Journal. 673-673. 2015
  • Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013.  European Heart Journal. 754-754. 2015
  • Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study.  European Heart Journal. 1043-1043. 2015
  • Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial.  European Heart Journal. 338-339. 2015
  • Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial.  European Heart Journal. 861-862. 2015
  • Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial.  European Heart Journal. 744-744. 2015
  • Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial.  European Heart Journal. 345-345. 2015
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment.  European Heart Journal. 340-340. 2015
  • Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation.  European Heart Journal. 345-345. 2015
  • Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative.  European Heart Journal. 195-195. 2015
  • The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation.  European Heart Journal. 887-888. 2015
  • The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice?.  European Heart Journal. 719-719. 2015
  • Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF.  European Heart Journal. 1083-1083. 2015
  • INFLUENZA VACCINATION AND INCIDENCE OF CKD: EFFECT MODIFICATION BY GEOGRAPHICAL ANCESTRY.  Nephrology Dialysis Transplantation. 2015
  • A tale of odorant and receptor: finding the best conformation.  Chemical Senses. 219-219. 2015
  • EFFECTS OF COGNITIVE REMEDIATION ON NEGATIVE SYMPTOMS DIMENSIONS: EXPLORING THE ROLE OF WORKING MEMORY.  Schizophrenia Bulletin. S40-S41. 2015
  • FINDING THE SITES OF GLUTAMATE CIRCUITRY ABNORMALITY IN SCHIZOPHRENIA WITH PROTON MRS.  Schizophrenia Bulletin. S260-S260. 2015
  • GABA AND GLUTAMATE DYSFUNCTION IN SCHIZOPHRENIA: DISTINGUISHING MEDICATION EFFECTS FROM NEUROBIOLOGY.  Schizophrenia Bulletin. S259-S260. 2015
  • Molecular Dynamics simulations reveal the active and inactive states of Olfactory Receptors.  Chemical Senses. 220-220. 2015
  • Three-year Change in the Wellbeing of Orphaned and Abandoned Children in Institutional and Family-Based Care Settings in Five Low and Middle Income Countries.  International Journal of Epidemiology. 216-217. 2015
  • A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score.  European Heart Journal. 357-357. 2014
  • Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial.  European Heart Journal. 867-867. 2014
  • Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure - insights from the platelet inhibition and patient outcomes (PLATO) trial.  European Heart Journal. 202-203. 2014
  • Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial.  European Heart Journal. 426-426. 2014
  • Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension.  European Heart Journal. 237-238. 2014
  • Impact of insurance status on survival in pulmonary hypertension.  European Heart Journal. 72-72. 2014
  • Incidence and impact of patent foramen ovale among patients with pulmonary hypertension.  European Heart Journal. 73-73. 2014
  • Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation.  European Heart Journal. 1115-1116. 2014
  • Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF.  European Heart Journal. 1033-1033. 2014
  • Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial.  European Heart Journal. 1052-1053. 2014
  • Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial.  European Heart Journal. 1162-1162. 2014
  • The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment.  European Heart Journal. 866-867. 2014
  • A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by.  European Heart Journal. 447-447. 2013
  • A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era.  European Heart Journal. 834-834. 2013
  • ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy.  European Heart Journal. 1040-1041. 2013
  • Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study.  European Heart Journal. 861-862. 2013
  • International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial.  European Heart Journal. 885-885. 2013
  • Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality?.  European Heart Journal. 341-341. 2013
  • Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow.  European Heart Journal. 350-351. 2013
  • Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial.  European Heart Journal. 99-99. 2013
  • Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE.  European Heart Journal. 98-99. 2013
  • Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR.  European Heart Journal. 418-418. 2013
  • HYPONATREMIA IN THE HOSPITAL SETTING: INTERIM RESULTS FROM A PROSPECTIVE, OBSERVATIONAL, MULTI-CENTER, GLOBAL REGISTRY.  Nephrology Dialysis Transplantation. 385-386. 2013
  • ASSOCIATION OF BASELINE CORTICOSTEROID WITH OUTCOMES IN A MULTIVARIATE ANALYSIS OF THE PHASE 3 AFFIRM STUDY OF ENZALUTAMIDE (ENZA), AN ANDROGEN RECEPTOR SIGNALING INHIBITOR (ARSI).  Annals of Oncology. 297-297. 2012
  • ASSOCIATION OF PROGRESSION BY PROSTATE CANCER WORKING GROUP (PCWG)-2 CRITERIA AND SURVIVAL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER.  Annals of Oncology. 297-298. 2012
  • OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC).  Annals of Oncology. 311-311. 2012
  • SURVIVAL AMONG METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A RANDOMIZED CONTROLLED TRIAL (RCT) VS AN OBSERVATIONAL COHORT STUDY (OCS).  Annals of Oncology. 191-191. 2012
  • TASQUINIMOD MECHANISM OF ACTION BIOMARKERS: CORRELATION WITH PFS AND SURVIVAL IN MEN WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATED IN A RANDOMIZED PHASE 2 TRIAL.  Annals of Oncology. 303-303. 2012
  • Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial.  European Heart Journal. 335-336. 2012
  • Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis.  European Heart Journal. 52-52. 2012
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia.  European Heart Journal. 281-282. 2012
  • Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial.  European Heart Journal. 685-686. 2012
  • Hemodynamic response to hypoxia in heart failure patients with high peripheral chemosensitivity.  European Heart Journal. 27-27. 2012
  • Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF.  European Heart Journal. 968-968. 2012
  • Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy.  European Heart Journal. 51-51. 2012
  • Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death.  European Heart Journal. 969-969. 2012
  • Ischemia change in heart failure patients with stable coronary artery disease is an independent predictor of death and myocardial infarction.  European Heart Journal. 1020-1020. 2012
  • NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin.  European Heart Journal. 51-51. 2012
  • New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics.  European Heart Journal. 142-142. 2012
  • Post-operative atrial fibrillation prophylaxis in clinical practice: results from the CAPS-Care STS registry.  European Heart Journal. 989-989. 2012
  • Predictors of augmented peripheral chemosensitivity in patients with systolic heart failure.  European Heart Journal. 937-937. 2012
  • Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection.  European Heart Journal. 82-83. 2012
  • Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial.  European Heart Journal. 519-519. 2012
  • Efficacy and safety of lisdexamfetamine dimesylate in adults with executive dysfunction and partial or full remission of major depressive disorder.  The International Journal of Neuropsychopharmacology. 189-189. 2012
  • HYPONATREMIA IN THE HOSPITAL SETTING: INTERIM Results FROM A PROSPECTIVE, OBSERVATIONAL, MULTI-CENTER, GLOBAL REGISTRY.  Nephrology Dialysis Transplantation. 74-74. 2012
  • A Program to Teach Moderate Sedation in the Gastrointestinal Endoscopy Suite.  British Journal of Anaesthesia. 366-367. 2012
  • Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy.  European Heart Journal. 116-116. 2011
  • SPECT MPI worsening ischemia and reclassification in CAD patients: a comparison of medical therapy versus revascularization.  European Heart Journal, Supplement. A48-A48. 2011
  • MODELING THE EXPRESSION AND COURSE OF DEVELOPMENTAL ABNORMALITIES PRECEDING ADULT SCHIZOPHRENIA: CHARACTERIZATION OF A NEW DEVELOPMENTAL ULTRA-HIGH-RISK GROUP IN 2 BIRTH COHORTS.  Schizophrenia Bulletin. 49-50. 2011
  • SLEEP PATTERNS OF INDIVIDUALS WITH SCHIZOPHRENIA.  Schizophrenia Bulletin. 277-277. 2011
  • PATIENT PREFERENCES FOR REDUCING TOXICITIES OF TREATMENTS FOR GASTROINTESTINAL STROMAL TUMOR (GIST): A CONJOINT ANALYSIS STUDY.  Annals of Oncology. 232-232. 2010
  • PATIENT PREFERENCES FOR TARGETED AGENTS IN RENAL CELL CARCINOMA (RCC): A BENEFIT RISK CONJOINT STUDY.  Annals of Oncology. 292-292. 2010
  • Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality.  European Heart Journal. 612-612. 2010
  • No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures.  European Heart Journal. 467-467. 2010
  • Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study.  European Heart Journal. 429-429. 2010
  • Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial.  European Heart Journal. 881-881. 2010
  • FOUR POLYMORPHISMS IN CYTOCHROME P450 1B1 (CYP1B1) GENE AND BREAST CANCER RISK: A META-ANALYSIS.  Annals of Oncology. 54-54. 2010
  • SAFETY UPDATE ON CERTOLIZUMAB PEGOL (CZP) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA).  Rheumatology (Oxford, England). I102-I103. 2010
  • THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.  Rheumatology (Oxford, England). I105-I105. 2010
  • Effect of Nicotinic Acetylcholine Receptor (nAChR) Blockers, Mecamylamine (Mec) and Dihydro-b-erthroidine (DH beta E) on the Chorda Tympani Responses to Nicotine in TRPM5 Knockout (KO) Mice.  Chemical Senses. A79-A79. 2009
  • Exploring the Interaction Between Odorants and Odorant Receptors Using Functional and Computational Methods.  Chemical Senses. A12-A13. 2009
  • Positive Selection Shapes the Function of an Odorant Receptor for Sex-Steroid Derived Odors in Primates.  Chemical Senses. A10-A10. 2009
  • Odotopic Properties of Odorants and the Expression Pattern of Olfactory Receptors.  Chemical Senses. E2-E3. 2009
  • Is there Functionality to the Spatial Distribution of Olfactory Receptors within Dorsal Zone of Olfactory Epithelium?.  Chemical Senses. S151-S151. 2008
  • Molecular and Cellular Mechanisms of Trigeminal Chemosensation.  Chemical Senses. S31-S31. 2008
  • A pilot study of myeloablative (MA) autologous stem cell (AutoSCT) followed by reduced intensity allogeneic transplantation (RI AlloSCT) in children with poor risk Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).  Annals of Oncology. 140-140. 2008
  • Clozapine increases the neurosteroid pregnenolone in rat hippocampus, cerebral cortex, and serum: Relevance to superior efficacy?.  Schizophrenia Bulletin. 319-319. 2007
  • Pregnenolone reductions in parietal cortex are associated with suicide in patients with schizophrenia.  Schizophrenia Bulletin. 308-308. 2007
  • Ovarian ablation or ovarian suppression versus chemotherapy for hormone receptor positive operable breast cancer: A meta-analysis.  Annals of Oncology. 161-162. 2007
  • Trastuzumab with adjuvant chemotherapy for resectable breast cancer: A meta-analysis.  Annals of Oncology. 166-166. 2007
  • A practical, validated model for prediction of risk in chronic heart failure.  European Heart Journal. 173-173. 2006
  • Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative.  European Heart Journal. 183-183. 2006
  • Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes.  European Heart Journal. 448-448. 2006
  • Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention.  European Heart Journal. 645-646. 2006
  • Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial.  European Heart Journal. 110-110. 2006
  • Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial.  European Heart Journal. 331-331. 2006
  • Deorphanizing'' mammalian odorant receptors.  Chemical Senses. A3-A3. 2006
  • Evidence that a volatile molecule, 3-decanol, in hermit crab blood signals shell availability to conspecifics.  Chemical Senses. A82-A82. 2006
  • Exploring the molecular receptive ranges of mammalian odorant receptors.  Chemical Senses. A97-A97. 2006
  • Functional analysis of the mouse odorant receptor MOR42 subfamily.  Chemical Senses. A96-A97. 2006
  • The functional properties of mammalian odorant receptors.  Chemical Senses. A65-A65. 2006
  • Novel anticancer drugs TLR9 agonists act by interfering with EGFR and VEGF signalling and synergize with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts.  Annals of Oncology. 137-137. 2006
  • Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (MRCC).  Annals of Oncology. 144-144. 2006
  • Phase II trial of sorafenib (bay 43-9006) in malignant mesothelioma: CALGB 30307.  Annals of Oncology. 216-217. 2006
  • Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies.  European Heart Journal. 268-269. 2005
  • Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM).  European Heart Journal. 378-379. 2005
  • Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme.  European Heart Journal. 381-381. 2005
  • Deriving a safety index from the GRACE risk score.  European Heart Journal. 566-566. 2005
  • Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events.  European Heart Journal. 621-621. 2005
  • Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.  European Heart Journal. 280-280. 2005
  • Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme.  European Heart Journal. 184-184. 2005
  • International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience.  European Heart Journal. 160-160. 2005
  • Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry.  European Heart Journal. 725-725. 2005
  • Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum.  European Heart Journal. 600-600. 2005
  • The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test.  European Heart Journal. 338-339. 2005
  • Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin.  European Heart Journal. 411-411. 2005
  • Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program.  European Heart Journal. 185-185. 2005
  • Disrupted task related activation to action selection and conflict resolution in patients with schizophrenia.  Schizophrenia Bulletin. 428-428. 2005
  • Neuroactive steroid alterations in schizophrenia and bipolar disorder: Negative ion chemical ionization gas chromatography/mass spectrometry investigations in posterior cingulate and parietal cortex.  Schizophrenia Bulletin. 253-253. 2005
  • Neuropsychological deficits at age 13 and later schizophreniform disorder: A longitudinal birth cohort study.  Schizophrenia Bulletin. 319-320. 2005
  • Olanzapine and fluoxetine effects on hippocampal pregnenolone and peripheral deoxycorticosterone: Relevance to therapeutic efficacy.  Schizophrenia Bulletin. 313-313. 2005
  • Importance of CHARM in relation to other heart failure trials with ARBs.  European Heart Journal, Supplement. H55-H60. 2004
  • Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.  Annals of Oncology. 13-14. 2004
  • Roles of the gibberellin-responsive SCL3 gene in Arabidopsis.  Plant & Cell Physiology. S213-S213. 2004
  • A zebrafish model for studying the neurobehavioral impacts of developmental chlorpyrifos exposure..  Toxicological Sciences. 129-129. 2003
  • Adrenergic receptor crosstalk during development: Adverse effect of tocolytics?.  Toxicological Sciences. 177-177. 2003
  • Changes in serotonin receptors in brain regions of rats after neonatal exposure to chlorpyrifos..  Toxicological Sciences. 124-125. 2003
  • Developmental neuro-and cardiotoxicity of terbutaline: DNA synthesis and neural biomarkers..  Toxicological Sciences. 124-124. 2003
  • Fetal chlorpyrifos exposure: Adverse effects on brain cell development and cholinergic biomarkers..  Toxicological Sciences. 124-124. 2003
  • Learning impairment caused by infusion of a toxin produced by Pfiesteria piscicida into the hippocampus of rats..  Toxicological Sciences. 71-71. 2003
  • Short-term nicotine exposure in adolescent rats elicits brain cell damage..  Toxicological Sciences. 124-124. 2003
  • Electronic health record: The need to prune.  Journal of the American Medical Informatics Association : Jamia. 881-881. 2001
  • Bayesian inference on latent structure in time series.  3-26. 1999
  • New data mining tools for outcomes analysis in complex clinical problems.  Journal of the American Medical Informatics Association : Jamia. 1068-1068. 1999
  • Regulation of platelet heparanase during inflammation.  Glycobiology. 1142-1142. 1998
  • The impact of fetal nicotine exposure on nervous system development and its role in sudden infant death syndrome.  89-97. 1998